Navigating cell therapy supply chain complexities during the COVID-19 pandemic

Abstract

Watch the video or read the poster to learn:Why COVID-19 is disrupting time-sensitive supply chains for the cell therapy industryHow Be The Match BioTherapies is addressing these challenges to deliver over 130 cell product shipments in a typical weekAbout the speakerErin Rasch is the Vice President of Sales and New Business Development for Be The Match BioTherapies. In her role, Erin identifies and cultivates new business opportunities with cell and gene therapy organizations. Rasch joined Be The Match BioTherapies with over 10 years of experience in the biotechnology development services industry. Most recently, Erin served as Vice President of Sales and Marketing at Cell Culture Company (C3), a Minneapolis-based contract manufacturing organization focused on providing cell culture services to clinical-stage pharmaceutical and diagnostic organizations. She was successful in rapidly growing the pipeline of that organization, establishing C3 as one of the premier organizations for small-scale GMP manufacturing in the U.S. Prior to C3, Erin worked at DCI-Biolafitte in Minnesota as a Sales Engineer, where she specialized in bioreactors and other process equipment. She began her career at Verenium Corporation in San Diego as a Manufacturing Process Engineer. Erin holds an M.S. in Bioengineering from the University of California, San Diego, and graduated summa cum laude with a B.S. in Chemical Engineering from Auburn University.